Oxitriptan

Uses

Medical

5-HTP is sold over-the-counter in the United States, France, Canada, Singapore, the Netherlands, and the United Kingdom as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid. It is also marketed in many European countries for the indication of major depressive disorder under the trade names Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum.

A 2002 review concluded that although the data evaluated suggests that 5-HTP is more effective than placebo in the treatment of depression, the evidence was insufficient to be conclusive due to a lack of clinical data meeting the rigorous standards of the day. More and larger studies using current methodologies are needed to determine if 5-HTP is truly effective in treating depression. In small, controlled trials, 5-HTP has also been reported to augment the antidepressant efficacy of the antidepressant clomipramine. A 2020 meta-analysis found oral 5-HTP supplementation had a large effect size on depression symptom severity. However, the included studies were considered relatively weak and the methods and treatment duration varied between the seven studies examined.

Other uses

At high doses, or in combination with carbidopa, 5-HTP has been used to treat obesity (by promoting weight loss).

Use after MDMA

MDMA is an empathogenic-entactogenic and serotonergic psychotropic drug used primarily for recreational, though sometimes also therapeutic, purposes. Among users of MDMA, the serotonergic effects of the drug are often of particular interest and concern: After consuming MDMA, serotonin concentrations are greatly reduced in the brain. 5-HTP is necessary for serotonin production and its concentrations in the brain also decrease after taking MDMA.

Side effects

Potential side effects of 5-HTP include heartburn, abdominal pain, nausea, vomiting, diarrhea, drowsiness, sexual problems, vivid dreams or nightmares, and muscle problems. Serotonin syndrome can occur.

Because 5-HTP has not been thoroughly studied in a clinical setting, possible side effects and interactions with other drugs are not well known. According to the US National Library of Medicine, 5-HTP has not been associated with serotonin syndrome or any serious adverse events in humans. Across multiple studies, 5-HTP has also been reported to not cause any noticeable hematological or cardiovascular changes. 5-HTP had also been associated with eosinophilia, but later studies have not found any causal connection.

Interactions

When combined with antidepressants of the MAOI or SSRI class, very high parenteral doses of 5-HTP can cause acute serotonin syndrome in rats. It is unclear if such findings have clinical relevance, as most drugs will cause serious adverse events or death in rodents at very high doses. In humans, 5-HTP has never been clinically associated with serotonin syndrome – although a case report suggests 5-HTP can precipitate mania when added to an MAOI.

When combined with carbidopa (as a treatment for symptoms of Parkinson's disease), 5-HTP causes nausea and vomiting; however, this can be alleviated via administration of granisetron. Cases of scleroderma-like illness have been reported in patients using carbidopa and 5-HTP.

Oral 5-HTP results in an increase in urinary 5-HIAA, a serotonin metabolite, indicating that 5-HTP is peripherally metabolized to serotonin, which is then metabolized. This might cause false positive results in tests looking for carcinoid syndrome. Due to the conversion of 5-HTP into serotonin by the liver, there could be a risk of heart valve disease from serotonin's effect on the heart, as based on preclinical findings. However, 5-HTP has not been associated with cardiac toxicity in humans.

It has been suggested that 5-HTP may cause eosinophilia-myalgia syndrome (EMS), a serious condition which results in extreme muscle tenderness, myalgia, and blood abnormalities. However, there is evidence to show that EMS was likely caused by a contaminant in certain 5-HTP supplements.

Pharmacology

The psychoactive action of 5-HTP is derived from its increase in production of serotonin in central nervous system tissue.

Research shows that co-administration with carbidopa greatly increases plasma 5-HTP levels. Other studies have indicated the risk of a scleroderma-like condition resulting from the combination of 5-HTP and carbidopa.

After oral administration, 5-HTP is absorbed by the upper intestine. With a decarboxylase inhibitor, the bioavailability of 5-HTP can be higher than 50%.

5-HTP is rapidly absorbed with a tmax of ≈1.5h, and rapidly eliminated with a half-life of ≈1.52h. Co-administration of a decarboxylase inhibitor (e.g., carbidopa, benserazide) doubles the half-life of 5-HTP to ≈34h,

5-HTP's short half-life (max](cmax-pharmacology) (time to maximal systemic concentration) drug spikes, and decreased clinical efficacy resulting from sub-therapeutic exposure for large parts of the day, when taken as a single dose unit or at intervals significantly larger than Cmax. It has been proposed that 5-HTP dosage forms achieving prolonged delivery would be more effective, For example, controlled-release oxycodone (OxyContin) or morphine (MS-Contin) are intended to, via novel delivery mechanisms, permit pain relief for up to twelve hours with an active ingredient which only provides relief for 3 to 6hours. However, the inherent variability amongst different people with respect to drug metabolism makes this task challenging.

Society and culture

Names

Oxitriptan is the generic name of the drug and its . Brand names of oxitriptan include Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum.

Regulatory status

There are currently no approved drug products containing 5-HTP approved by the FDA. All available 5-HTP products are nutraceuticals and are as such not regulated or verified for purity, integrity, or clinical efficacy or safety, mandating caution regarding human consumption.

As of 25 August 2020, Hungary added 5-HTP to the controlled psychoactive substances list, prohibiting production, sale, import, storage and use, becoming the first country to do so.

Natural sources

The seeds of the Griffonia simplicifolia, a climbing shrub native to West Africa and Central Africa, are used as an herbal supplement for their 5-HTP content. In one 2010 trial, Griffonia simplicifolia extract appeared to increase satiety in overweight women.

Research

In clinical trials of various design, 5-HTP has also been reported to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia. However, these clinical findings, as for all therapeutic findings with 5-HTP, are preliminary and need confirmation in larger trials.

Oxitriptan/carbidopa combination

A combination of oxitriptan and carbidopa, oxitriptan/carbidopa, is being developed for the potential treatment of depression.

Slow-release formulation

5-HTP's short half-life is impractical for chronic drug therapy. Research conducted at Duke University in mice has demonstrated that 5-HTP when administered as slow-release appears to gain drug properties. Slow-release delivery attenuates or abolishes the peaks and valleys in 5-HTP exposure during treatment. Slow-release delivery of 5-HTP markedly improved the safety profile of 5-HTP and conferred stable plasma exposure of 5-HTP and strong and sustained enhancement of brain serotonin function. This discovery indicates that 5-HTP slow-release medications represent a new avenue for treatment of brain disorders responsive to serotonergic enhancement.

References

References

1. (December 2020). "5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology". Int J Mol Sci.
2. (2003). "Dietary Supplements: Toxicology and Clinical Pharmacology". Humana.
3. (March 2006). "Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan". Pharmacol Ther.
4. (13 June 2005). "Oxitriptan: Uses, Interactions, Mechanism of Action".
5. "Oxitriptan".
6. Swiss Pharmaceutical Society. (2000). "Index Nominum 2000: International Drug Directory (Book with CD-ROM)". Medpharm Scientific Publishers.
7. (2002). "Tryptophan and 5-hydroxytryptophan for depression". The Cochrane Database of Systematic Reviews.
8. "5-Hydroxytryptophan (5-HTP)". University of Maryland Medical Center.
9. (May 2011). "Second-tier natural antidepressants: review and critique". Journal of Affective Disorders.
10. (1982). "Serotonin precursors in the treatment of depression". Advances in Biochemical Psychopharmacology.
11. (1974). "5-hydroxytryptophan in combination with clomipramine in "therapy-resistant" depressions". Psychopharmacologia.
12. (1983). "Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study". International Journal of Clinical Pharmacology Research.
13. (January 2020). "Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis". Nutrition Reviews.
14. (July 2010). "Combinations of drugs in the Treatment of Obesity". Pharmaceuticals.
15. (2017). "Off-label drugs for weight management". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.
16. "5-HTP". U.S. National Library of Medicine.
17. "5-Hydroxytryptophan, C11H12N2O3, CID 144 - PubChem".
18. (Jun 1987). "5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects". J Clin Psychopharmacol.
19. (2004). "Safety of 5-hydroxy-L-tryptophan". Toxicol. Lett..
20. (July 2008). "Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats". European Journal of Pharmacology.
21. (February 2006). "Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats". European Journal of Pharmacology.
22. (2012). "Mania following addition of hydroxytryptophan to monoamine oxidase inhibitor". General Hospital Psychiatry.
23. (January 2010). "Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron". Journal of Psychopharmacology.
24. "Carbidopa/Levodopa". Truestarhealth.com.
25. (January 2008). "Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake". Canadian Journal of Gastroenterology.
26. (January 2013). "'Sweet Dreams', 'Happy Days' and elevated 24-h urine 5-hydroxyindoleacetic acid excretion". Annals of Clinical Biochemistry.
27. (March 2005). "Long-term serotonin administration induces heart valve disease in rats". Circulation.
28. (December 2002). "Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells". The American Journal of Pathology.
29. (Mar 2006). "Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan". Pharmacol. Ther..
30. (December 1994). "An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan". The Journal of Rheumatology.
31. "5-HTP: Uses, Side Effects, Interactions and Warnings - WebMD".
32. (September 1981). "Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man". Acta Pharmacologica et Toxicologica.
33. (October 1980). "Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa". The New England Journal of Medicine.
34. (March 2012). "Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration". Eat Weight Disord..
35. (April 1980). "Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state". Acta Pharmacologica et Toxicologica.
36. (July 1978). "The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man". Acta Pharmacologica et Toxicologica.
37. (April 2002). "Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers". Journal of Clinical Psychopharmacology.
38. (November 2016). "Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale". Trends in Pharmacological Sciences.
39. (September 2005). "Assessment of the feasibility of oral controlled release in an exploratory development setting". Drug Discovery Today.
40. (2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer US.
41. (2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Netherlands.
42. Swiss Pharmaceutical Society. (2000). "Index Nominum 2000: International Drug Directory (Book with CD-ROM)". Medpharm Scientific Publishers.
43. "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations".
44. "5-HTP: MedlinePlus Supplements". U.S. National Library of Medicine.
45. [https://magyarkozlony.hu/hivatalos-lapok/fsmDhb9y0CRKX2SkxRDw5f37b222dc2d1/dokumentumok/bc9ef7aef40a107a518ab17e1ac35adf2735e291/letoltes MAGYARORSZÁG HIVATALOS LAPJA]. Retrieved 2021-04-28.
46. "5-Hydroxytryptophan (5-HTP)". University of Maryland Medical Center.
47. (2010). "An open-label trial of L-5-hydroxytryptophan in subjects with romantic stress". Neuro Endocrinology Letters.
48. (September 2004). "5-hydroxy-L-tryptophan". National Center for Biotechnology Information.
49. (March 2012). "Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration". Eating and Weight Disorders.
50. (1990). "Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome". J Int Med Res.
51. (1980). "Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations". Ann Neurol.
52. (1981). "5-OH-Tryptophane in migraine: clinical and neurophysiological considerations". J Neurol.
53. (Nov 1988). "Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing". Arch Neurol.
54. (Aug 2016). "SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept". Neuropsychopharmacology.
55. (2005). "Assessment of the feasibility of oral controlled release in an exploratory development setting". Drug Discov Today.